Solvonis Therapeutics (LSE:SVNS) Asset Impairment Charge : £0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics Asset Impairment Charge?

Solvonis Therapeutics's Asset Impairment Charge for the three months ended in Sep. 2024 was £0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 was £0.00 Mil.

Solvonis Therapeutics Asset Impairment Charge Historical Data

The historical data trend for Solvonis Therapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solvonis Therapeutics Asset Impairment Charge Chart

Solvonis Therapeutics Annual Data

Trend

May18

May19

May20

May21

Dec22

Dec23

Dec24

Asset Impairment Charge

Get a 7-Day Free Trial

Solvonis Therapeutics Quarterly Data
	May18	May19	May20	May21	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
Asset Impairment Charge	Get a 7-Day Free Trial								-	-	-	-	-

Solvonis Therapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was £0.00 Mil.

Solvonis Therapeutics Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Solvonis Therapeutics's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Solvonis Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF

Website

https://www.solvonis.com

Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Solvonis Therapeutics Headlines

No Headlines